A5001141427- Glioma Diagnosis and Treatment
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Brain Metastases and Treatment
- Axon Guidance and Neuronal Signaling
- MicroRNA in disease regulation
- Microtubule and mitosis dynamics
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Pluripotent Stem Cells Research
- Neurogenesis and neuroplasticity mechanisms
- Single-cell and spatial transcriptomics
- Cancer Genomics and Diagnostics
- Hedgehog Signaling Pathway Studies
- 3D Printing in Biomedical Research
- Histone Deacetylase Inhibitors Research
- RNA modifications and cancer
- Ubiquitin and proteasome pathways
- Ferroptosis and cancer prognosis
- Chemical Reactions and Isotopes
- Cancer Mechanisms and Therapy
- Mechanisms of cancer metastasis
- RNA Interference and Gene Delivery
- Neuroblastoma Research and Treatments
McMaster University
2016-2025
Discovery Centre
2012-2024
Oregon Institute of Technology
2023-2024
Indian Institute of Technology Hyderabad
2023
Queen's University
2023
Nagaland University
2022
McMaster Children's Hospital
2014-2020
McMaster University Medical Centre
2015-2018
Population Health Research Institute
2018
Cancer Research Institute
2017
Glioblastoma (GBM) patients suffer from a dismal prognosis, with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence cancer stem cells (CSCs) drives the extensive heterogeneity seen in GBM, prompting need for novel therapies specifically targeting this subset tumor-driving cells. Here, we identify CD70 as potential therapeutic target GBM CSCs.
Abstract Medulloblastoma is the most common malignant brain tumor in children. This disease heterogeneous and composed of four subtypes medulloblastoma [WNT, Sonic Hedgehog (SHH), Group 3, 4]. An immediate goal to identify novel molecular targets for aggressive forms medulloblastoma. Polo-like kinase 1 (PLK1) an oncogenic that controls cell cycle proliferation, making it a strong candidate treatment. In this study, pediatric medulloblastomas were subtyped two patient cohorts (discovery...
The reported risk factors for glioblastoma (GBM), i.e., ionizing radiation, Li-Fraumeni syndrome, Neurofibromatosis I, and Turcot also increase the of other brain tumor types. Risk human GBM are associated with different oncogenic mutation profiles. Pedigreed domestic dogs a shorter nose flatter face (brachycephalic dogs) display relatively high rates glioma formation. genetic profiles canine gliomas idiosyncratic. association putatively mutational patterns in humans canines suggests that...
Glioblastoma multiforme (GBM) ranks among the deadliest types of cancer and given these new therapies are urgently needed. To identify molecular targets, we queried a microarray profiling 467 human GBMs discovered that polo-like kinase 1 (PLK1) was highly expressed in tumors it clustered with proliferative subtype. Patients PLK1-high were more likely to die from their disease suggesting current inactive against such tumors. This prompted us examine its expression brain tumor initiating cells...
Brain metastases are most common in adults with lung cancer, predicting uniformly poor patient outcome, a median survival of only months. Despite their frequency and severity, very little is known about tumorigenesis brain metastases. We applied previously developed primary solid tumor-initiating cell models to the study from evaluate presence cancer stem population. Patient-derived (n = 20) NCI-H1915 line were cultured as stem-enriching tumorspheres. used vitro limiting-dilution...
Abstract Brain tumors represent the leading cause of childhood cancer mortality, which medulloblastoma (MB) is most frequent malignant tumor. Recent studies have demonstrated presence several MB molecular subgroups, each distinct in terms prognosis and predicted therapeutic response. Groups 1 2 are characterized by relatively good clinical outcomes activation Wnt Shh pathways, respectively. In contrast, groups 3 4 (“non-Shh/Wnt MBs”) distinguished metastatic disease, poor patient outcome,...
// Mohini Singh 1, 4 , Neha Garg 6 Chitra Venugopal Robin Hallett 2 Tomas Tokar 7 Nicole McFarlane Sujeivan Mahendram David Bakhshinyan Branavan Manoranjan 3, Parvez Vora Maleeha Qazi Carolynn C. Arpin 10 Brent Page Sina Haftchenary A. Rosa Ping-Shan Lai Rodolfo F. Gómez-Biagi Ahmed M. Ali 11 Andrew Lewis Mulu Geletu Naresh K. Murty John Hassell 2, 4, 5 Igor Jurisica 7, 8, 9 Patrick T. Gunning Sheila 1 McMaster Stem Cell and Cancer Research Institute, University, Hamilton, Ontario,...
Clonal evolution of cancer may be regulated by determinants stemness, specifically self-renewal, and current therapies have not considered how genetic perturbations or properties stemness affect such functional processes. Glioblastoma-initiating cells (GICs), identified expression the cell surface marker CD133, are shown to chemoradioresistant. In study, we sought elucidate role CD133 in self-renewal identify compounds that can target this CD133(+) treatment-refractory population.Using...
Medulloblastoma (MB), the most common malignant paediatric brain tumor, is currently treated using a combination of surgery, craniospinal radiotherapy and chemotherapy. Owing to MB stem cells (MBSCs), subset patients remains untreatable despite standard therapy. CD133 used identify MBSCs although its functional role in tumorigenesis has yet be determined. In this work, we showed enrichment Group 3 associated with increased rate metastasis poor clinical outcome. The signal transducers...
Abstract Glioblastoma (GBM) carries a dismal prognosis and inevitably relapses despite aggressive therapy. Many members of the Eph receptor tyrosine kinase (EphR) family are expressed by GBM stem cells (GSC), which have been implicated in resistance to In this study, we identify several EphRs that mark therapeutically targetable GSC population treatment-refractory, recurrent (rGBM). Using highly specific EphR antibody panel CyTOF (cytometry time-of-flight), characterized expression all 14...
Abstract Medulloblastoma (MB) is defined by four molecular subgroups (Wnt, Shh, Group 3, 4) with Wnt MB having the most favorable prognosis. Since prior reports have illustrated antitumorigenic role of activation in Shh MB, we aimed to assess effects activated canonical signaling 3 and 4 MBs. By using primary patient-derived brain tumor-initiating cell (BTIC) lines, characterize differences capacity Wnt, MB. With single RNA-seq technology, demonstrate presence rare Wnt-active cells non-Wnt...
Abstract Despite tremendous research efforts, successful targeting of aberrant tumor metabolism in clinical practice has remained elusive. Tumor heterogeneity and plasticity may play a role the failure metabolism-targeting interventions for treating cancer patients. Moreover, compensatory growth-related processes adaptive responses exhibited by heterogeneous subpopulations to metabolic inhibitors are poorly understood. Here, using clinically-relevant patient-derived glioblastoma (GBM) cell...
Abstract Glioblastoma (GBM) remains a formidable challenge in neuro-oncology, characterized by heterogeneity and aggressive tumor growth. The identification of novel biomarkers therapeutic targets is crucial for advancing promising therapies. This study profiled patient-derived samples utilizing single-cell RNA sequencing proteomics platforms to uncover the upregulation glycoprotein non-metastatic melanoma protein B (GPNMB) cells, particularly post-treatment recurrent as well...
Abstract Resistance to genotoxic therapies and tumor recurrence are hallmarks of glioblastoma (GBM), an aggressive brain tumor. In this study, we investigated functional drivers post-treatment recurrent GBM through integrative genomic analyses, genome-wide genetic perturbation screens in patient-derived models independent lines validation. Specific dependencies were found consistent across models, accompanied by increased mutational burden differential transcript protein expression compared...